Eledon Pharmaceuticals
ELDN
32 hedge funds and large institutions have $48.2M invested in Eledon Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 14 increasing their positions, 1 reducing their positions, and 4 closing their positions.
1,300% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 1
144% more capital invested
Capital invested by funds: $19.8M → $48.2M (+$28.4M)
75% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 4
10% more funds holding
Funds holding: 29 → 32 (+3)
7.77% more ownership
Funds ownership: 39.65% → 47.42% (+7.8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ZP
Zimmer Partners
New York
|
+$5.04M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$4.69M |
| 3 |
SSA
Schonfeld Strategic Advisors
New York
|
+$3.46M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$3.1M |
| 5 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$1.43M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$186K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$32.9K |
| 3 |
Millennium Management
New York
|
-$28.6K |
| 4 |
Wells Fargo
San Francisco,
California
|
-$389 |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$45 |
ELDN Hedge Fund Activity: Q2 2024 in Review
32 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Eledon Pharmaceuticals (ELDN) for Q2 2024, worth a combined $48.2M — up 144% from $19.8M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new ELDN positions and 4 closed out — a net gain of 3 holders — while 14 added to existing stakes and 1 trimmed.
The largest buyer was Zimmer Partners, opening a new position worth an estimated $5.04M. The largest seller was Susquehanna International Group, cutting an estimated $186K.
- 32 institutional investors held Eledon Pharmaceuticals (ELDN) as of Q2 2024, up from 29 in Q1 2024.
- Funds reported $48.2M of Eledon Pharmaceuticals stock for Q2 2024, up 144% quarter-over-quarter.
- 7 funds opened new Eledon Pharmaceuticals positions in Q2 2024 and 4 closed out, a net change of +3 holders.
- The largest Eledon Pharmaceuticals buyer in Q2 2024 was Zimmer Partners, an estimated $5.04M added.
- The largest Eledon Pharmaceuticals seller in Q2 2024 was Susquehanna International Group, an estimated $186K sold.
Based on aggregated 13F filings for Q2 2024.